Cangrelor: an emerging therapeutic option for patients with coronary artery disease

  title={Cangrelor: an emerging therapeutic option for patients with coronary artery disease},
  author={Jacek Kubica and Marek Koziński and Eliano Pio Navarese and Udaya S Tantry and Aldona Kubica and Jolanta M. Siller-Matula and Young-Hoon Jeong and Tomasz Fabiszak and Anna Andruszkiewicz and Paul A. Gurbel},
  journal={Current Medical Research and Opinion},
  pages={813 - 828}
Abstract Objectives: To perform a systematic up-to-date review and critical discussion of potential clinical applications of cangrelor based on its pharmacologic properties and the main findings from randomized clinical studies. Methods: A database search (PubMed, CENTRAL and Google Scholar) by two independent investigators, including proceedings from scientific sessions of ACC, AHA, ESC, TCT and EuroPCR, from January 1998 through December 2013. Results: Cangrelor is a potent, intravenous… 
Cangrelor for the treatment of patients with Arterial Thrombosis
Any high-risk patient with ST-segment elevation myocardial infraction or patient who is unable to take oral medications is a potential candidate for intravenous cang Relor therapy, and stable patients with coronary artery disease, who are considered for ad hoc PCI following coronary angiography, may be considered for treatment with cangrelor to reduce post-PCI thrombotic events.
Role of New Antiplatelet Drugs on Cardiovascular Disease: Update on Cangrelor
In clinical trials, cangrelor has demonstrated greater efficacy than clopidogrel with a favorable safety profile among PCI patients not receiving pretreatment with oral P2Y12 antagonists, but its definitive role in contemporary practice is yet to be determined.
Impact of ticagrelor administration strategy on its pharmacokinetics and pharmacodynamics in patients with unstable angina pectoris: a protocol of a randomized study
This study is expected to provide essential evidence-based data on the impact of ticagrelor administration strategy on its pharmacokinetics and pharmacodynamics in patients with unstable angina pectoris.
New directions for pharmacotherapy in the treatment of acute coronary syndrome
Introduction of cangrelor and ezetimibe, and potentially future recognition of proprotein convertase subtilisin/kexin type 9 antibodies, are likely to alter the landscape of ACS pharmacotherapy.
Novel Antiplatelet Agents in Cardiovascular Medicine
Personalized antiplatelet therapy based on therapeutic winnow concept for P2Y12 receptor blocker may facilitate the balance between reducing ischemic events and avoiding bleeding events, thereby improving net clinical outcome.
Personalized antiplatelet therapy with P2Y12 receptor inhibitors: benefits and pitfalls
Results of all recent trials of potent antiplatelets and prolonged antiplatelet durations point towards a need for individualizedAntiplatelet approach in order to decrease thrombotic events without increasing bleeding.
Anaphylaxis-triggered takotsubo syndrome: What is its prevalence?
  • J. Madias
  • Medicine, Biology
    The American journal of emergency medicine
  • 2016
Evaluating current and emerging antithrombotic therapy currently available for the treatment of acute coronary syndrome in geriatric populations
The authors critically summarize recently published research on contemporary and emerging antithrombotic therapy for the treatment of ACS in geriatric patients and suggest that elderly ACS patients should receive treatment according to the general recommendations.
Comparison of Ticagrelor Pharmacokinetics and Pharmacodynamics in STEMI and NSTEMI Patients (PINPOINT): protocol for a prospective, observational, single-centre study
The PINPOINT study is a phase IV, single-centre, investigator-initiated, prospective, observational study designed to compare the pharmacokinetics and pharmacodynamics of ticagrelor in patients with STEMI and NSTEMI assigned to the invasive strategy of treatment.


Cangrelor: a review on its mechanism of action and clinical development
An overview of the current status of knowledge on cangrelor is provided, focusing on its pharmacologic properties, clinical development and potential future applications.
Update on the clinical development of cangrelor
An overview of the current status of knowledge on cangrelor is provided, focusing on its pharmacologic properties and clinical development, to show why it is a promising drug for clinical use.
Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial.
Among patients who discontinue thienopyridine therapy prior to cardiac surgery, the use of cangrelor compared with placebo resulted in a higher rate of maintenance of platelet inhibition.
Platelet inhibition with cangrelor in patients undergoing PCI.
Cangrelor was not superior to an oral loading dose of 600 mg of clopidogrel, administered 30 minutes before PCI, in reducing the composite end point of death from any cause, myocardial infarction, or ischemia-driven revascularization at 48 hours.
Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials
A rapid platelet inhibitory effect was achieved during cangrelor infusion and a rapid offset of action after treatment discontinuation, demonstrating its potent P2Y12 receptor inhibitory effects, and rapid onset/offset of action.
Intravenous platelet blockade with cangrelor during PCI.
The use of periprocedural cangrelor during PCI was not superior to placebo in reducing the primary end point, and the prespecified secondary end points of stent thrombosis and death were lower in the cang Relor group, with no significant increase in the rate of transfusion.
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
In patients who have an acute coronary syndrome with or without ST-segment elevation, treatment with ticagrelor as compared with clopidogrel significantly reduced the rate of death from vascular causes, myocardial infarction, or stroke without an increase in the rates of overall major bleeding but with an increase of non-procedure-related bleeding.